Feromics: Revolutionizing Iron Biology for Human Health

Feromics, a biotechnology company based in Toronto, Canada, is pioneering a new frontier in health innovation through its focus on iron biology. The company is developing a first-in-class platform to detect, monitor, and modulate iron at the molecular level—an area of research with far-reaching implications for chronic diseases.

At the helm of this transformative work is Dr. Shai Schubert, CEO and Co-Founder of Feromics—and a member of Convisero. Dr. Schubert is driven by a mission to bring cutting-edge treatments to underserved patients. Before launching Feromics, he co-founded and led technology development in several biotechnology and medical device companies.

Dr. Schubert holds a Ph.D. in biotechnology from the Technion – Israel Institute of Technology and completed his postdoctoral training at the prestigious Harvard-MIT Program in Health Sciences and Technology (HST), Biomedical Engineering Center. His multidisciplinary expertise and entrepreneurial leadership are central to Feromics' vision of redefining iron biology for clinical innovation.

Iron, a vital mineral in the human body, plays a key role in oxygen transport, energy production, and immune function. However, dysregulated iron levels have been linked to a wide range of health conditions, including inflammation, neurodegenerative diseases, cardiovascular disorders, and cancer.

Feromics' platform leverages cutting-edge tools in molecular diagnostics, bioinformatics, and protein engineering to provide more precise, non-invasive insights into iron metabolism. Their mission is to harness this knowledge to improve clinical outcomes, from early detection and prevention to personalized treatments.

Learn more about their work:
Feromics – Company Website